Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 21 Oct 2021
Delivery of Novavax vaccine may be delayed in Australia due to reported manufacturing issues
21 October 2021 - Australians may not get access to the Novavax vaccine this year with reports of manufacturing problems causing ...
Posted by Michael Wonder on 21 Oct 2021
NICE recommends gene silencing therapy for porphyria patients on NHS
21 October 2021 - NICE have recommended the use of givosiran, a gene silencing therapy, on the NHS in England, as ...
Posted by Michael Wonder on 21 Oct 2021
COVID-19 vaccine weekly safety report (21 October 2021)
21 October 2021 - To 17 October 2021, approximately 32.7 million vaccine doses have been given in Australia – 18.3 million ...
Posted by Michael Wonder on 21 Oct 2021
Tasmania's Pharmacy Guild wants antiviral COVID-19 pills available in all pharmacies
20 October 2021 - Tasmania has a stockpile of two different antiviral pill products which are sitting in the Royal ...
Posted by Michael Wonder on 21 Oct 2021
FDA grants breakthrough device designation for Biological Dynamics’ early stage pancreatic cancer detection test
20 October 2021 - Designation provides expedited regulatory review of Exo-PDAC, a liquid biopsy assay, built on the company’s Verita ...
Posted by Michael Wonder on 20 Oct 2021
Stealth BioTherapeutics receives refusal to file letter from the FDA
20 October 2021 - Stealth BioTherapeutics today announced that it received a Refusal to File letter from the United States FDA ...
Posted by Michael Wonder on 20 Oct 2021
FDA expands approval of Dupixent (dupilumab) to include children aged 6 to 11 years with moderate to severe asthma
20 October 2021 - Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years ...
Posted by Michael Wonder on 20 Oct 2021
Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges
20 October 2021 - Medical devices are potentially good candidates for coverage with evidence development schemes, as clinical data at market ...
Posted by Michael Wonder on 20 Oct 2021
ICER publishes final evidence report and policy recommendations on therapies for myasthenia gravis
20 October 2021 - Independent appraisal committee found the evidence is adequate to demonstrate that eculizumab and efgartigimod both provide a ...
Posted by Michael Wonder on 20 Oct 2021
Sales of Biogen’s costly new Alzheimer’s drug fall far short of expectations
20 October 2021 - The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 ...
Posted by Michael Wonder on 20 Oct 2021
Luminopia announces FDA approval of digital therapeutic that uses TV shows to improve vision in children with lazy eye
20 October 2021 - Luminopia One improves vision in children with amblyopia, the leading cause of vision loss in children, and ...
Posted by Michael Wonder on 20 Oct 2021
PHARMAC says all patients who meet criteria will get next generation diabetes drugs, despite concerns
20 October 2021 - PHARMAC says it will fund next generation diabetes drugs for all people with the condition who ...
Posted by Michael Wonder on 20 Oct 2021
TGA approves Brukinsa for another use
20 October 2021 - The second approval for zanubrutinib this month. ...
Posted by Michael Wonder on 20 Oct 2021
Pear Therapeutics launches Pear Prescription Digital Therapeutics Digest, provides roadmap for payer coverage considerations
19 October 2021 - Pear Therapeutics, in collaboration with Avalere Health, today launched the Pear Prescription Digital Therapeutics Digest at ...
Posted by Michael Wonder on 20 Oct 2021
Chiesi Global Rare Diseases announces approval of Ferriprox (deferiprone) in Canada for the treatment of iron overload in sickle cell disease
15 October 2021 - Chiesi Global Rare Diseases announced today that Health Canada has approved Ferriprox (deferiprone) for the treatment of ...